X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
ITM-11 consists of two components: the medical radioisotope non-carrier-added lutetium-177 (n.c.a. 177Lu) and the targeting molecule edotreotide, a synthetic form of the peptide hormone somatostatin that targets neuroendocrine tumor-specific receptors.
Lead Product(s): Lutetium-177-edotreotide
Therapeutic Area: Oncology Product Name: ITM-11
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2022
Details:
ITM-11 (n.c.a. 177Lu-edotreotide), as first- or second-line treatment compared to best standard of care for patients with well-differentiated aggressive grade 2 and grade 3 somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Lead Product(s): Lutetium-177-edotreotide
Therapeutic Area: Oncology Product Name: ITM-11
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2022
Details:
ITM-11 is a Targeted Radionuclide Therapy consisting of the high-quality beta-emitting radioisotope, no-carrier-added lutetium-177 (n.c.a. 177Lu) combined with the tumor-specific targeting molecule edotreotide.
Lead Product(s): Lutetium-177-edotreotide
Therapeutic Area: Oncology Product Name: ITM-11
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2022
Details:
The equity investment follows the licensing agreement between companies which provides GP with rights to develop, manufacture and commercialize ITM’s precision oncology radiopharmaceutical candidates, ITM-11 (n.c.a. 177Lu-edotreotide) and ITM-41 (n.c.a. 177Lu-zoledronate).
Lead Product(s): Lutetium-177-edotreotide,L-Arginine,Lysine
Therapeutic Area: Oncology Product Name: ITM-11
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Grand Pharmaceutical Group Limited
Deal Size: $588.4 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 16, 2022
Details:
Under the terms of the agreement, ITM grants GP an exclusive license for the ITM-11 (n.c.a. 177Lu-edotreotide) and ITM-41 (n.c.a. 177Lu-zoledronate), in the licensed territory and will support the supply of the pharmaceuticals needed for clinical and commercial activities.
Lead Product(s): Lutetium-177-edotreotide,L-Arginine,Lysine
Therapeutic Area: Oncology Product Name: ITM-11
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Grand Pharmaceutical Group Limited
Deal Size: $588.4 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 27, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
